De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ONCR Overzicht aandelen
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Oncorus, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.13 |
| 52 Week Hoogtepunt | US$0.47 |
| 52 Week Laag | US$0.01 |
| Bèta | 1.95 |
| 11 maand verandering | 500.00% |
| 3 maanden verandering | 427.20% |
| 1 Jaar Verandering | -58.00% |
| 33 jaar verandering | -99.63% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -99.21% |
Recent nieuws en updates
Recent updates
Oncorus GAAP EPS of -$0.74 misses by $0.02
Aug 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Oct 14
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Jul 09Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans
May 05What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?
Feb 26Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels
Feb 02Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.
Jan 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Jan 04Oncorus reports Q3 results
Nov 11Rendement voor aandeelhouders
| ONCR | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 26.0% | -0.2% | -0.4% |
| 1Y | -58.0% | 22.1% | 34.1% |
Rendement versus industrie: ONCR underperformed the US Biotechs industry which returned 7.1% over the past year.
Rendement versus markt: ONCR underperformed the US Market which returned 22.4% over the past year.
Prijsvolatiliteit
| ONCR volatility | |
|---|---|
| ONCR Average Weekly Movement | 210.0% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: ONCR's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: ONCR's weekly volatility has increased from 101% to 210% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2015 | 64 | Craig Jalbert | www.oncorus.com |
Oncorus, Inc. Samenvatting
| ONCR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$3.29m |
| Inkomsten(TTM) | -US$90.54m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs ONCR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ONCR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$90.54m |
| Inkomsten | -US$90.54m |
Laatst gerapporteerde inkomsten
Mar 31, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.47 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 66.0% |
Hoe presteerde ONCR op de lange termijn?
Bekijk historische prestaties en vergelijking